GGrantIndex
← Search

Clinical Protocol and Data Management

$676,114P30FY2023CANIH

University Of Wisconsin-Madison, Madison WI

Investigators

Linked publications, trials & patents

Paper 39638850Paper 39604703Paper 39580301Paper 39530524Paper 39527745Paper 39516197Paper 39484544Paper 39481346Paper 39474803Paper 39462136Paper 39452931Paper 39444276Paper 39443360Paper 39432401Paper 39414902Paper 39408582Paper 39407431Paper 39402986Paper 39399121Paper 39386576Paper 39386545Paper 39379374Paper 39374311Paper 39364328Paper 39358429Paper 39345631Paper 39335130Paper 39312186Trial NCT06608511Trial NCT06557733Trial NCT05985681Trial NCT05521698Trial NCT05107219Trial NCT03725761Trial NCT03722030Trial NCT03703492Trial NCT03656276Trial NCT03393741Trial NCT03387514Trial NCT03358563Trial NCT03356470Trial NCT03342378Trial NCT03304002Trial NCT03300557Trial NCT03209869Trial NCT03185871Trial NCT03028584Trial NCT03023202Trial NCT02955043Trial NCT02917629Trial NCT02876640Trial NCT02780401Trial NCT02719821Trial NCT02169284Trial NCT02096783Trial NCT02095145Trial NCT01999881Trial NCT01935960Trial NCT01901835Trial NCT01707004Trial NCT01625156Trial NCT01325311Trial NCT01263613Trial NCT01245205Trial NCT01243359Trial NCT01233505Trial NCT01218620Trial NCT01217450Trial NCT01158274Trial NCT01083641Trial NCT01004796Trial NCT00896974Trial NCT00666562Trial NCT00544596Trial NCT00499135Trial NCT00462969Trial NCT00415025Trial NCT00410605Trial NCT00227513Trial NCT00138203Trial NCT00109863Trial NCT00079014Trial NCT00052832Trial NCT00049712Trial NCT00036790Trial NCT00028652Trial NCT00023855Trial NCT00022412Trial NCT00005794Trial NCT00004872Patent 9867974Patent 9763597Patent 9603567Patent 9470697Patent 9161720Patent 8871458Patent 6974254Patent 6438202Patent 6114119Patent 6020178

Abstract

ABSTRACT – CLINICAL PROTOCOL AND DATA MANAGEMENT The Clinical Research Central Office (CRCO) provides the centralized infrastructure for clinical research activities at the University of Wisconsin Carbone Cancer Center (UWCCC). The CRCO has 110 FTEs supporting 170 faculty PIs with an annual operating budget of $8.58M. The CCSG provides $311K annually (directs) of the total budget. Under the leadership of Center Director Dr. Howard Bailey (CPC) and Associate Director for Clinical Research, Dr. Kari Wisinski (DT), the CRCO has built upon the success of the prior efforts of expansion and centralization of the CRCO to increase accrual to treatment intervention studies and reduce activation timelines. The CRCO has central administration and services (fiscal, regulatory, informatics, compliance, education, etc.) and Disease-Oriented Teams (DOTs) to lead study activation and coordination. In 2021, the CRCO supported accrual of ~4,700 subjects to 538 research studies across the center. Of the 278 treatment intervention trials open during 2021, the sponsor breakdown was: 11 Externally peer-reviewed (4%), 107 Industrial (38%), 53 Institutional (19%), and 107 National (38%). UWCCC achieved an increase in accrual to treatment intervention studies from 319 in 2017 to 474 in 2021. Other key successes included expansion of a clinical trial navigation team and establishment of the UWCCC-led statewide Precision Medicine Molecular Tumor Board (PMMTB). These efforts facilitated high accrual of patients with catchment area priority cancers, rare tumors, and enrollment to genomically-driven studies. A new protocol intake management system, study activation huddles, and a dedicated activation team for NCI studies improved activation timelines by 23%. Staff turnover was stabilized with remote work options, supported by enhanced technology, and an improved career advancement pathway. The CRCO supports clinical research conducted on site, through multiple networks, including NCTN, ETCTN, and statewide and national investigator-initiated trial (IIT) networks (e.g. Wisconsin Oncology Network, Big Ten Cancer Research Consortium). Research informatics has expanded and CRCO leadership has optimized bi- directional communication strategies with DOT leaders and staff. CRCO leadership is actively engaged with the newly-established Oncology Service Council under Dr. Lee Wilke (TM), improving integration of research and clinical care. The QA/Compliance team executes the UWCCC DSMP, enacting risk-based monitoring, determined by study sponsorship and PRMC-adjudicated risk level. In collaboration with the UWCCC Community Outreach and Engagement Office Cancer Health Disparities Initiative, the CRCO has multiple new efforts to improve the accrual of underrepresented in medicine (URM) and rural individuals to clinical trials, including increased translation services; targeted media outreach; and dedicated community navigator support in DOTs. CRCO initiatives strive toward continued improvements in activation timelines, expanded access and accrual to genomically-driven, theranostic, and immunotherapy studies, especially for URM, and increased patient opportunities for tissue and data sharing in alignment with the UWCCC strategic plan.

View original record on NIH RePORTER →